3-Dimensional Mapping System: The PULSTAR Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 149 participants.

Also called NCT05618340

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 149 participants (enrolled count) (from the registry)
Sponsor
Shanghai Shangyang Medical Technology Co., Ltd. (from the registry)
Registry
  • NCT NCT05618340
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05618340. Allocation not applicable; no masking; primary purpose treatment. Start 2022-09-26 (actual); primary completion 2024-03-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
3-Dimensional Mapping System: The PULSTAR Study
Condition
Paroxysmal Atrial Fibrillation
Intervention (Device)
Pulsed electric field ablation device;Cardiac Pulsed Electric Field Ablation Catheter
Lead sponsor
Shanghai Shangyang Medical Technology Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05618340
Content hash
23516052a975c29101597e41372b05044c635d784b2dfa32485850583dbd17cf